Dr. Karen L. Reckamp

Dr. Karen L. Reckamp, MD, MS, is a prominent thoracic oncologist and translational researcher celebrated for her contributions to the treatment of lung cancer and other thoracic malignancies. She is Director of the Division of Medical Oncology at Cedars-Sinai Cancer and Associate Director for Clinical Research at Cedars-Sinai Cancer Center. Dr. Reckamp earned her medical degree from the University of Chicago Pritzker School of Medicine, followed by residency at Barnes-Jewish Hospital at Washington University in St. Louis and fellowship training in hematology/oncology at City of Hope. She also holds a Master of Science in Clinical Investigation, reflecting her deep commitment to integrating research and clinical care.

Dr. Reckamp is best known for her pioneering work in targeted therapies and immunotherapies for non-small cell lung cancer (NSCLC), particularly in identifying biomarkers that inform treatment selection and resistance mechanisms. She has led multiple groundbreaking clinical trials and has been a driving force behind innovative therapeutic strategies that extend survival and improve quality of life for patients with advanced thoracic cancers. Her research is widely published in leading medical journals, and she has helped shape national and international treatment guidelines through her involvement in collaborative research networks and professional panels.

A respected mentor and advocate for patient-centered research, Dr. Reckamp has dedicated her career to advancing the science and delivery of cancer care. She actively participates in key oncology societies, including the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer, contributing to education, policy, and clinical innovation. Through her unwavering dedication to translational science, clinical excellence, and compassionate care, Dr. Reckamp continues to influence the future of thoracic oncology on both a national and global stage.